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Background: Mortality in non-cystic fibrosis bronchiectasis (NCFB) is known to be influenced by a number of fac-
tors such as gender, age, smoking history and Pseudomonas aeruginosa, but the impact of traffic related air pollution
indicators on NCFB mortality is unknown.
Methods: We followed 183 patients aged 18 to 65 years with a HRCT proven diagnosis of NCFB and typical
symptoms, who had visited the outpatient clinic at the University Hospital of Leuven, Belgium, between June 2006
and October 2012. We estimated hazard ratios (HR) for mortality in relation to proximity of the home to major
roads and traffic load, adjusting for relevant covariables (age, gender, disease severity, chronic macrolide use,
smoking history, socioeconomic status and Pseudomonas aeruginosa colonization status).
Results: Fifteen out of the 183 included patients died during the observation period. Residential proximity to a
major road was associated with the risk of dying with a HR 0.28 (CI 95% 0.10-0.77; p = 0.013) for a tenfold increase
in distance to a major road. Mortality was also associated with distance-weighted traffic density within 100 meters
(HR for each tenfold increase in traffic density 3.80; CI 95% 1.07-13.51; p = 0.04) and 200 meters from the patient’s
home address (HR for each tenfold increase in traffic density 4.14; CI 95% 1.13-15.22; p = 0.032).
Conclusion: Traffic-related air pollution appears to increase the risk of dying in patients with NCFB.
Trial registration: The study was approved by the local ethical committee of the UZ Leuven, Belgium (ML-5028),
registered at ClinicalTrial.gov (NCT01906047).
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Both acute and chronic air pollution exposure have been
shown to influence cystic fibrosis (CF) bronchiectatic
disease. Ambient concentrations of ozone, PM10 and
NO2 play a role in triggering an exacerbation in CF and
annual average exposures to particulate air pollution was
associated with an increased risk of pulmonary exacerba-
tions and a decline in lung function [1,2]. Non-cystic fi-
brosis bronchiectatic (NCFB) disease is characterized by
chronic bronchial inflammation caused by inappropriate
clearance of various microorganisms and recurrent or
chronic infections [3]. Mortality in NCFB is known to be* Correspondence: pieter.goeminne@student.kuleuven.be
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article, unless otherwise stated.influenced by a number of factors such as gender, age,
smoking history and Pseudomonas aeruginosa, but data
on the impact of air pollution on NCFB mortality are
lacking [4,5]. More recently, De Soyza and colleagues
formulated some research priorities in NCFB disease [6].
One of the three priorities is more research into epi-
demiology, to identify certain patient subgroups at risk
for worse disease.
As the impact of air pollution in NCFB has not been
studied before, our primary aim was to study the associ-
ation between residential distance to a major road and
death in a cohort of patients with NCFB. Secondary aims
were to evaluate the distance-weighted traffic density at
100 and 200 meters from the patient’s residence.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patient population
The study was based on the computerized notes of all
patients between the age of 18 and 65 years who had a
diagnosis of NCFB and had visited the outpatient clinic
specifically dedicated to this condition at the University
Hospital of Leuven, Belgium, between June 2006 and
October 2012. Death was analyzed until end of Novem-
ber 2013. All patients had chronic productive cough and
a chest HRCT scan confirming the diagnosis of NCFB
[7]. All patients with a concomitant diagnosis of COPD
were excluded from the analysis. HRCT scans were eval-
uated by two experienced radiologists. Images obtained
using 1 mm collimation at full inspiration were reviewed
and bronchiectasis was deemed to be present if one or
more of the following criteria were fulfilled: a bronch-
oarterial ratio greater than 1, lack of tapering of the
bronchi and visualization of bronchi within 1 cm of cos-
tal or paravertebral pleura or abutting the mediastinal
pleura [7]. To further establish cause of the NCFB, each
patient was evaluated with serum protein electrophor-
esis, immunoglobulins (IgA, IgE, IgM, IgG, IgG1–3), spe-
cific IgE and IgG against Aspergillus fumigatus, nasal
NO measurement, sputum microbiology and an ororhi-
nolaryngological evaluation. CF was excluded guided by
clinical indication and using a sweat test, nasal potential
difference, CF genotype screening or CF gene sequencing.
Additional investigations were guided by clinical indication.
The following patient data were collected for analysis:
home address at time of start of follow-up (which did
not differ from home address at time of death), age, gender,
smoking history, spirometric values at diagnosis (FEV1,
FVC), type of bronchiectatic lesion (cylindrical, varicous
or cystic), number of lobes affected, Pseudomonas aerugi-
nosa infection status according to criteria by Lee and col-
leagues [8], chronic azithromycin use (a minimum dose of
250 mg three times a week during at least three consecu-
tive months), socioeconomic status (SES: coded for each
household and condensed into a scale with scores ranging
from 1 (low) to 3 (high), taking into account occupation
and the highest level of education reached by the house-
holds’ reference person or his/her partner [9-12]) and ex-
acerbation frequency (recalled number of exacerbations in
the year prior to inclusion; an exacerbation was defined as
the need for antibiotic treatment due to respiratory symp-
toms). For all patients, death was assessed each six months
in the patient file and if death occurred, the patient file
was reassessed to identify cause of death. No patients were
lost during follow-up.
Distance-weighted traffic density
Previous research showed that airborne exhaust pollutants
spread around a source in a Gaussian manner [13-15]. We
observed a log linear association between survival anddistance to major road. This means that the risk decreases
more rapidly at shorter distances and flattens off at higher
distances. In the construction of the distance-weighted
traffic density analysis, we assumed the airborne spread
around a source in a Gaussian manner and the impact
of traffic was modeled as a function of the traffic intensity
and the distance to the road according to the following
equation:
Y ¼ 1




where D is the distance to the road and Y is the corre-
sponding weight. The shape of the equation reflects the
assumption that 96% of emissions disperse at 150 meters
from the road, which is based on research that investi-
gated the dispersion of vehicle exhaust pollutants [16-18].
We calculated distance-weighted traffic density in a buffer
around each residential address by adding up the traffic
intensity weighted by the distance. The resulting values
were transformed logarithmically to normalize the distri-
bution. Traffic intensity within a buffer was measured by
the number of kilometers travelled by all vehicles during
one day. The total length of the roads within each buffer
was calculated using the Geographical Information System
(GIS, ArcMap version 10.0). Information about the average
number of vehicles on highways and other major roads was
available from a network of measuring stations run by the
Department of Mobility and Public Works of the Flemish
Region. For minor local roads, no traffic counts were
available. To include these traffic roads in our calcula-
tions, we made an estimation of the number of vehicles
on the local roads. In order to estimate the number of
vehicles on these non-major roads, we used information
about their total length and the number of kilometers
travelled on these roads in Flanders, which resulted in
the average of 543 cars per day, a figure which was used
in our calculations [19].
Statistics
Cox proportional hazard regression analysis was used to
estimate hazard ratios (HR) and the 95% confidence inter-
vals (CI) for mortality in assocation to proximity of the
home to major roads and traffic load, adjusting for relevant
covariables (age, gender, smoking history, SES, disease
severity, chronic azithromycin use and Pseudomonas
aeruginosa colonization status). Analysis was performed
using SAS 9.3. No a priori sample size calculations were
done given the fixed study population.
Ethical committee
The study was approved by the local ethical committee
of the University Hospital Gasthuisberg, Leuven, Belgium
Table 1 Patient characteristics
Number of patients 183
Gender M/F 45%/ 55%
Median age (years) 53 [IQR 37–59]
FEV1% 73.2% ± 25.8
FVC% 88.2% ± 25.3
Type of bronchiectasis Cylindrical 61.2% (n = 112)
Varicous 23.5% (n = 43)
Cystic 15.3% (n = 28)
n° of lobes affected One 20.8% (n = 38)
Two 26.2% (n = 48)
Three 29.5% (n = 54)
Four 15.8% (n = 29)
Five 7.7% (n = 14)
Exacerbations in previous year 2 [IQR 1–3]
Socioeconomic status Low 51% (n = 93)
Middle 46% (n = 84)
High 3% (n = 6)
Smoking history Never smokers 64% (n = 118)
Passive smokers 2% (n = 3)
Former smokers 19% (n = 35)
Active smokers 15% (n = 27)
Etiology Idiopathic 30% (n = 56)
Postinfectious 20% (n = 37)
PCD 16% (n = 29)
Miscellaneous 13% (n = 23)
Immunodeficiency 8% (n = 15)
ABPA 7% (n = 12)
Rheumatic 6% (n = 11)
Pseudomonas aeruginosa status Chronic colonization 12.5% (n = 23)
Deaths (events) 15 events
Long-term antibiotic use
- Azithromycin use 56% (n = 103)
Miscellaneous causes include sarcoidosis (5%), anatomic malformations (4%),
inflammatory bowel disease (2%), aspiration (1%), vasculitis (1%). Deaths were
due to respiratory failure (n = 10), kidney failure with a severe respiratory
infection (n = 1), lymphoma with severe pneumonia (n = 1), pancreatic cancer
with severe pneumonia (n = 1), alcohol intoxication with cardiorespiratory
arrest (n = 1) and unknown (n = 1). ABPA = allergic bronchopulmonary
aspergillosis; F = female; IQR = Interquartile range; M =male; PCD = primary
ciliary dyskinesia; ± = standard deviation. Passive smokers were never smokers
with high smoking exposure due to smoking peers or due to professional
exposure. Exacerbations were the recalled number of antibiotic events in the
year prior to inclusion.
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In total, we included 183 patients (55% female; 53 years,
IQR 37–59), the majority of them having never smoked
and having either an idiopathic (30%) or postinfectious
(20%) cause of their bronchiectasis. There was a median
follow-up time of 5.5 years (IQR 3.9-6.3). Over the study
period, we registered 15 deaths. The majority of deaths
had a direct respiratory cause (10 deaths; 67%; respiratory
failure most often due to infection) or an admission due
to respiratory problems causing further deterioration of
the underlying disease status (one renal failure initially ad-
mitted for a severe respiratory infection/exacerbation; two
non-respiratory end-stage tumors admitted due to severe
pneumonia with further systemic complications and de-
terioration). Two patients had no clear respiratory cause
for death or initial admission (one alcoholic patient died
due to alcohol intoxication and cardiorespiratory arrest;
one patient died of an unknown cause). Further patient
characteristics are summarized in Table 1.
Pollution results
Unadjusted model
Unadjusted analysis showed that residential proximity to
a major road was associated with the risk of dying, giving
a HR of 0.47 (CI 95% 0.23-0.97; p = 0.042) for a tenfold in-
crease in distance to a major road. In other words, living
e.g. at 50 m from a major road was associated with a dou-
bled risk (1 divided by 0.47) of dying compared to living
500 m away from a major road. Further analysis revealed
a trend towards a significant association between the risk
of dying and distance-weighted traffic density in a 100
meter buffer from patient’s home address (HR for each
tenfold increase in traffic density 2.1; CI 95% 0.80-5.73;
p = 0.13) with a similar trend for distance-weighted traffic
density in a 200 meter buffer from the patient’s residence
(HR for each tenfold increase in traffic density 2.3; CI 95%
0.82-6.27; p = 0.11).
Adjusted for age and gender
Adjusting for age and gender, residential proximity to a
major road was associated with the risk of mortality, giv-
ing a HR 0.46 (CI 95% 0.22-0.96; p = 0.039) for a tenfold
increase in distance to a major road. Analyzing the risk
of dying and distance-weighted traffic density, a trend
was seen for a 100 meter buffer from patient’s home ad-
dress (HR for each tenfold increase in traffic density 2.1; CI
95% 0.77-5.68; p = 0.14) with a similar trend for distance-
weighted traffic density in a 200 meter buffer from the pa-
tient’s residence (HR for each tenfold increase in traffic
density 2.24; CI 95% 0.80-6.27; p = 0.12).Adjusting for multiple factors
Adjusting for age, gender, chronic Pseudomonas aerugi-
nosa status, smoking history, number of lobes affected,
type of bronchiectatic lesion, FEV1, FVC, SES and macro-
lide therapy, residential proximity to a major road was as-
sociated with the risk of mortality, giving a HR of 0.28 (CI
95% 0.10-0.77; p = 0.013) for a tenfold increase in distance
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major road was associated with an almost fourfold (1 di-
vided by 0.28) higher risk of dying than living 500 m away
from a major road. Using the same adjusting factors, a sig-
nificant association between the risk of dying and the
distance-weighted traffic density was found in a 100 meter
(HR for each tenfold increase in traffic density 3.80; CI
95% 1.07-13.51; p = 0.04) and 200 meter buffer from pa-
tient’s home address (HR for each tenfold increase in traf-
fic density 4.14; CI 95% 1.13-15.22; p = 0.032). Excluding
the patient with the unknown cause of death and adjust-
ing for previously mentioned covariates, results still
showed a significant association between risk of dying and
residential proximity to a major road (HR 0.26; CI 95%
0.09-0.74; p = 0.01). Similarly, no changes were perceived
in the results for distance-weighted traffic density in a 100
meter (p = 0.036) and 200 meter (p = 0.035) buffer from
the patient’s home address after exclusion of that patient.
Discussion
Our analysis showed that residential proximity to a major
road was linked to an increased risk of dying in patients
with NCFB. Further analysis suggested that distance-
weighted traffic density is an important factor in this risk.
We describe for the first time the impact of traffic related
chronic air pollution exposure indicators in a NCFB popu-
lation. With the exception of cystic fibrosis, there is a
striking paucity of research into bronchiectasis [6]. For
cystic fibrosis, chronic and acute air pollution exposure
have been linked to exacerbations [1,2], but the impact on
mortality has not been established yet. For other respira-
tory and cardiovascular diseases, research clearly indicates
a pronounced negative effect on mortality. Air pollution
triggers myocardial infarction [20], it is associated with
cardiopulmonary mortality [21], and causes an increased
risk of infant mortality [22]. In respiratory disease, it has
been linked with lung cancer [21] and mortality or bron-
chiolitis obliterans syndrome after lung transplantation
[23]. For COPD, an interquartile range elevation in black
carbon concentrations is associated with a 7% increase
in COPD mortality [24]. We now added NCFB to the in-
creasing list of respiratory diseases where mortality is
affected by traffic related air pollution.
To further strengthen our data, we also analyzed distance-
weighted traffic density, and demonstrated a significant ef-
fect in a buffer of 100 and 200 meters from the patient’s
residence. This is in line with previous literature showing
that cardiopulmonary mortality is associated with living
near a major road [25-27].
It is known that air pollution affects mortality in the
general population. Carey and colleagues found that in
their nationwide English cohort of 835,607 people, resi-
dential pollution concentration was associated with mor-
tality with a HR of 1.02, 1.03 and 1.04 for PM2.5, NO2 andSO2 respectively. [28] Similar effect sizes of pollution in
the general population have been seen by other groups
[21,29], and are much lower than the effects we describe
in our NCFB population. A possible reason might be the
superimposed effect of air pollution on the vicious cycle of
inflammation, infection and mucus plugging with proteo-
lytic enzymatic actions. Whether air pollution also leads
to a higher exacerbation rate, remains to be established.
These results again emphasize the ongoing need to
sensitize policy makers in reducing traffic and air pollution
[30]. Cesaroni et al. elegantly showed that a reduction in
traffic in the city center of Rome not only effectively re-
duced air pollution, but also caused an average life gain of
3.4 days per person for the more than a quarter million
residents living along the busy roads [31].
Our study has some limitations. The most important
limitation is the low number of events. We aimed at inves-
tigating a hard endpoint in NCFB, i.e. death. However,
NCFB is not a very lethal condition and our 15 deaths
among 183 patients over the course of our study period
are in line with the rates from literature. Loebinger and
colleagues showed only 27 deaths among their 91 patients
over a 13-year period (29.7%) [4]. This limited number of
events forces us to be cautious when interpreting our
results regarding the effect of pollution. We further tried
to refine our exposure assessment by adding distance-
weighted traffic density analysis. The association between
mortality and traffic density within distances of either 100
or 200 meters from the patient’s home address, adds to
the suggestion that there is a real effect of air pollution
and traffic density on mortality.
On the other hand, a second limitation of our study
might be overadjustment for covariates in our multivariate
model. Correcting for many factors (gender, age, disease
severity, SES, chronic macrolide use, chronic colonization
by Pseudomonas aeruginosa and smoking history) when
there are only few events might have led to overadjust-
ment and therefore an incorrect estimation of the effect.
On the other hand, the unadjusted model and the model
where we only correct for age and gender resulted in simi-
lar significant effects. The largely similar results of both
the adjusted and unadjusted models therefore suggest that
this limitation probably had a limited effect on our overall
outcome.
Thirdly, as one patient had an unknown cause of
death, this death might be unrelated to air pollution.
We preferred all-cause mortality as our primary out-
come as this is a strong objective end-point which is not
biased or influenced by confounders. When excluding
this patient from the analysis, residential proximity to a
major road was still associated with risk of dying as were
the results for distance-weighted traffic density. A sec-
ond patient had a cardiorespiratory arrest and alcohol
intoxication. We included this patient as literature has
Goeminne et al. Respiratory Research 2014, 15:108 Page 5 of 6
http://respiratory-research.com/content/15/1/108shown that air pollution is known also to affect cardio-
vascular mortality [20].
In this analysis, we did not address seasonality and
temporal changes. The traffic counts are based on annual
average traffic counts on working days in 2010 and no in-
formation on seasonality is available. However, we believe
that, as we studied a chronic outcome, even if a seasonal
variation in traffic density would exist, the spatial variation
is more important than potential temporal variation.
Concerns might be raised on changes in distribution
of distance to a major road and traffic density. However,
Pearson et al. previously showed that an increase in traffic
over an eleven-year period still shows highly correlated
densities [14].
Finally, for minor roads, the traffic intensity data was
missing for some local roads and therefore these missing
data were imputed with a default value of 543 vehicles
per day. We believe that, as these roads were minor
roads, measurement error with regard to defining busy
and non-busy roads is likely small. This default setting is
based on average counts on local roads and has been used
in previous large studies on traffic related air pollution [32].
In conclusion, we found that living close to a major
road is associated with a higher risk of dying in patients
with NCFB. We interpret this as reflecting yet another
adverse effect of air pollution.
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